Gsk Share Discussion Threads

[tradermichael] 08/11/2022 10:11

GSK now has:
8 new products at Registration
18 new entities at Phase III
21 new entities at Phase II
35 new entities at Phase I

[garycook] 08/11/2022 00:53

TM,Thanks, Seeing we will receive 67p for 2022,then adjusted for HLN spin off 61.25p.2023 agreed 56.25p

[alphorn] 07/11/2022 16:18

The main issue is of course incremental sales. Big pharma has to run like crazy just to stand still as drugs come off IPP. To give a balanced picture both sides should be presented. (No current position).

[dr biotech] 07/11/2022 16:01

Yep. To put things in perspective this article from last year shows the expected sales of blenrep and other "new" GSK drugs. Doesn't mean its a dead product as it does have some efficacy, but its more likely to be used when other therapy fails, so sales will be much smaller.

hxxps://www.evaluate.com/vantage/articles/news/corporate-strategy/new-glaxo-its-all-about-late-stage-assets

[netcurtains] 07/11/2022 15:56

So what percentage of revenue/profits etc was this new drug meant to achieve for SSK?
Eg what percentage should the share price fall due to the "failure" of this drug?

Has anyone got a very rough idea?

[spoole5] 07/11/2022 15:53

Always something with this company

[dr biotech] 07/11/2022 14:21

Blenrep was one of the key drivers for revenues going forward. For it to fail the trial is a significant blow.

[tradermichael] 07/11/2022 13:34

Gary, for the next two GSK financial years,

2022: It expects to pay a total dividend for the year of 61.25p per new share.

2023: It expects to declare a dividend of 56.25p per share for 2023.

[tradermichael] 07/11/2022 13:08

RSharman and alexis, et al., almost certainly due to disappointing initial results. However, Glaxo said data from the trial will be shared with health authorities and discussions are currently ongoing, with additional trials of Blenrep continuing as planned as follows:.

GSK said additional trials within the DREAMM clinical trial programme will continue. They are designed to demonstrate the benefit of Blenrep in combination treatment with novel therapies and standard-of-care treatments in earlier lines of therapy.

The company expects data from the DREAMM-7 and DREAMM-8 phase III trials in the first half of 2023. These are combination treatment trials, designed to test the efficacy of Blenrep in combination with bortezomib and dexamethasone, and pomalidomide and dexamethasone, respectively.

[netcurtains] 07/11/2022 13:03

I'm assuming it's the drug trial. It doesn't take much to knock a thinly traded stock downwards.

I guess once fall stops, its a buying opportunity, provided no more news. I'll wait to see what the press says.

[tuftymatt] 07/11/2022 13:01

Yeah I agree. Picked a few more up today though as this will continue on into and past the 14's before too long in my opinion.

[alexisk] 07/11/2022 12:49

Price drop is possibly due to GSK's drug for mutiple myeloma, Blenrep.having disappointing result in a trial.

[rsharman] 07/11/2022 12:29

Hi TM why price crash today - any ideas?

[xtomo] 07/11/2022 10:46

Ex div on 17th 13.75. Payment on 12 Jan.

[garycook] 07/11/2022 10:33

TM or any other shareholder can you confirm the exact dividend payments for 2023.Are they 13.75p x 3 plus 15p for the Q4 dividend giving 56.25p for the year.Also did I read on GSK 3Q results somewhere that the Dividend drops to 45p for 2024

[tradermichael] 06/11/2022 12:11

GSK PLC said Thursday that it will stop patient recruitment early for two trials of gepotidacin, a treatment for urinary tract infections, following a recommendation by the Independent Data Monitoring Committee.

The pharmaceutical giant said that the decision was based on a pre-specified interim analysis of efficacy and safety data in more than 3,000 patients across the trials. However, it added that the IDMC review didn't identify any safety concerns.

The EAGLE-2 and EAGLE-3 trials met the primary efficacy endpoint, GSK said. The company also said that it plans to submit a new drug application for gepotidacin with the U.S. Food and Drug Administration in the first half of next year.

"The IDMC's recommendation to stop the EAGLE-2 and 3 trials early for efficacy provides GSK with the opportunity to engage regulatory authorities as we work together to bring a new class of antibiotics to patients with uUTIs [Uncomplicated urinary tract infections]," GSK's senior vice president for development Chris Corsico said.

[geckotheglorious] 03/11/2022 16:15

In case anyone interested...

"Efficacy and Safety of Bivalent Respiratory Syncytial Virus (RSVpreF)
Vaccine in Older Adults"

[tradermichael] 03/11/2022 12:18

Bank of England raises interest rates to 3%

[suetballs] 03/11/2022 10:12

Although "alleged" you still have to defend yourself - unfortunately.
Suet

[anhar] 03/11/2022 10:12

After the close of day 1 trading, GSK consolidated its existing shares, returning the share price to around the same as before demerger. This was to ensure comparability of the company’s earnings per share and share price with previous periods

Not really, that's just the BS they tell you. The real reason for these consolidations following demergers and cash returns is cosmetic and face-saving, ie. to avoid what they see as the shame arising from the price fall that would have to occur without the consol. There's no real need for such consols at all, but I guess they make a few bucks for the advisers.

[tradermichael] 03/11/2022 10:05

Add 'no causal link has been scientifically proven'

[alphorn] 03/11/2022 09:43

Add 'alleged'.

[lippy4] 03/11/2022 09:37

reported today in the telegraph that gsk have put aside £45 million to fight the claims being made against it for selling the cancer causing drug..

[tradermichael] 03/11/2022 09:22

After the close of day 1 trading, GSK consolidated its existing shares, returning the share price to around the same as before demerger. This was to ensure comparability of the company’s earnings per share and share price with previous periods